Myasthenia Gravis News and Research

RSS
Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Symptoms vary in type and severity. Myasthenia gravis is not directly inherited nor is it contagious.
Protein once seen as promising anti-cancer compound helps to stabilize neural circuits

Protein once seen as promising anti-cancer compound helps to stabilize neural circuits

Immune system play role in memory impairment associated with chronic epilepsy

Immune system play role in memory impairment associated with chronic epilepsy

Autoimmune diseases share certain pathogenic mechanisms with cancer

Autoimmune diseases share certain pathogenic mechanisms with cancer

Researchers collaborate to tackle rare diseases

Researchers collaborate to tackle rare diseases

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Dr. Reddy's Laboratories launches Moxifloxacin Hydrochloride Tablets

Dr. Reddy's Laboratories launches Moxifloxacin Hydrochloride Tablets

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Norwegian researchers map genetic variations associated with increased risk of MS and MG

Norwegian researchers map genetic variations associated with increased risk of MS and MG

Researchers develop new microsystem for testing drugs to treat epilepsy, MG and cystic fibrosis

Researchers develop new microsystem for testing drugs to treat epilepsy, MG and cystic fibrosis

Georgia University scientists identify cause of muscle weakness disease myasthenia gravis

Georgia University scientists identify cause of muscle weakness disease myasthenia gravis

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Study focuses on vaccine-preventable illnesses in myasthenia gravis patients

Study focuses on vaccine-preventable illnesses in myasthenia gravis patients

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

FDA approves Allergan’s BOTOX to treat overactive bladder

FDA approves Allergan’s BOTOX to treat overactive bladder

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA